Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CD38 | P28907 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 6/20 | 0.39 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027656 | 0.91 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL6027454 | 0.89 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL6110394 | 0.88 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL6028379 | 0.88 | CYP1A2 (0.51) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL6027411 | 0.84 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5901978 | 0.83 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4914164 | 0.83 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL6028335 | 0.82 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL6028099 | 0.79 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5901795 | 0.78 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194782-A1 | Pharmacologically active imidazo[4,5-c] pyridines | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1670795-A1 | PHARMACOLOGICALLY ACTIVE IMIDAZO 4,5-C PYRIDINES | ALTANA Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005026164-A1 | PHARMACOLOGICALLY ACTIVE IMIDAZO[4,5-C]PYRIDINES | ALTANA PHARMA AG (DE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194782-A1 | Pharmacologically active imidazo[4,5-c] pyridines | GIPR, VIP, PGC | CYP3A4 29/4885CYP2C9 578/4885CYP1A2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.